GATHERING GROUP'S STUDY TO EXAMINE THE IMPACT OF PSILOCYBIN (4-PHOSPHORYLOXY-N,N-DIMETHYLTRYPTAMINE) IN ASSISTED GROUP THERAPY ON …

Aug 18, 2025 · Emerging psychedelic therapies show promise for treating depression but require further research. This pilot study aimed to evaluate the feasibility, safety, and preliminary …

Participants will receive either a full dose of psilocybin (25 mg) with therapy or a low-dose placebo (1 mg) with therapy. We will closely monitor safety, feasibility, and treatment effects over four …

Withdrawal from serotonergic antidepressant drugs is a common prerequisite for taking part in trials of psilocybin due to the possibility of ongoing antidepressant drugs altering the...

Oct 2, 2025 · The purpose of this study is to determine the role of psilocybin monitors on the effects of psilocybin therapy in adults with treatment resistant depression.

Jan 9, 2025 · Psilocybin research in Canada represents an emerging area of clinical investigation that is contributing to our understanding of mental health care. Clinical studies of this …

Jun 23, 2025 · COMP360 showed a statistically significant reduction in TRD symptom severity compared to placebo, with a clinically meaningful MADRS score difference. The COMP005 …

Apr 24, 2025 · The active placebo is a substance that looks identical to the study medication but contains less therapeutic ingredients, and thus is less capable of producing the transformative …

This study is a 12-week (in addition to up to 30 days of screening) randomized, double-blind, placebo-controlled, parallel-group trial.

This open-label pilot clinical trial examined the effectiveness, feasibility and safety of psilocybin with psychotherapeutic support for treatment-resistant depression (TRD).